These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 29756563)

  • 61. [Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity].
    Dammann HG
    Z Gastroenterol; 1999 Jan; 37(1):45-58. PubMed ID: 10091284
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The role of nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors on experimental colitis.
    Paiotti AP; Marchi P; Miszputen SJ; Oshima CT; Franco M; Ribeiro DA
    In Vivo; 2012; 26(3):381-93. PubMed ID: 22523290
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cyclooxygenases in hepatocellular carcinoma.
    Cervello M; Montalto G
    World J Gastroenterol; 2006 Aug; 12(32):5113-21. PubMed ID: 16937518
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives.
    Bruno A; Tacconelli S; Patrignani P
    Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):56-63. PubMed ID: 23953622
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Brief Story on Prostaglandins, Inhibitors of their Synthesis, Hematopoiesis, and Acute Radiation Syndrome.
    Hofer M; Hoferová Z; Falk M
    Molecules; 2019 Nov; 24(22):. PubMed ID: 31698831
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Inducible cyclooxygenase may have anti-inflammatory properties.
    Gilroy DW; Colville-Nash PR; Willis D; Chivers J; Paul-Clark MJ; Willoughby DA
    Nat Med; 1999 Jun; 5(6):698-701. PubMed ID: 10371510
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Inflammation: Biochemistry, cellular targets, anti-inflammatory agents and challenges with special emphasis on cyclooxygenase-2.
    Kaur B; Singh P
    Bioorg Chem; 2022 Apr; 121():105663. PubMed ID: 35180488
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cyclooxygenase-2-selective inhibitors: translating pharmacology into clinical utility.
    Cronstein BN
    Cleve Clin J Med; 2002; 69 Suppl 1():SI13-9. PubMed ID: 12086289
    [TBL] [Abstract][Full Text] [Related]  

  • 69. New approaches to the modulation of the cyclooxygenase-2 and 5-lipoxygenase pathways.
    González-Périz A; Clària J
    Curr Top Med Chem; 2007; 7(3):297-309. PubMed ID: 17305572
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept.
    Celotti F; Laufer S
    Pharmacol Res; 2001 May; 43(5):429-36. PubMed ID: 11394934
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of cyclooxygenase inhibition on the gastrointestinal tract.
    Radi ZA; Khan NK
    Exp Toxicol Pathol; 2006 Nov; 58(2-3):163-73. PubMed ID: 16859903
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [The role of cyclooxygenase and prostaglandins in the pathogenesis of rheumatoid arthritis].
    Stańczyk J; Kowalski ML
    Pol Merkur Lekarski; 2001 Nov; 11(65):438-43. PubMed ID: 11852819
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Potential adverse effects of cyclooxygenase-2 inhibition: evidence from animal models of inflammation.
    Colville-Nash PR; Gilroy DW
    BioDrugs; 2001; 15(1):1-9. PubMed ID: 11437671
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.
    Baraf HS
    Curr Pharm Des; 2007; 13(22):2228-36. PubMed ID: 17691996
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Discovery of a potent cyclooxygenase-2 inhibitor, S4, through docking-based pharmacophore screening, in vivo and in vitro estimations.
    Tseng TS; Chuang SM; Hsiao NW; Chen YW; Lee YC; Lin CC; Huang C; Tsai KC
    Mol Biosyst; 2016 Jul; 12(8):2541-51. PubMed ID: 27265567
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Nonsteroidal Anti-Inflammatory Drugs: Exploiting Bivalent COXIB/ TP Antagonists for the Control of Cardiovascular Risk.
    Carnevali S; Buccellati C; Bolego C; Bertinaria M; Rovati GE; Sala A
    Curr Med Chem; 2017; 24(30):3218-3230. PubMed ID: 28571535
    [TBL] [Abstract][Full Text] [Related]  

  • 77. COX inhibitors: a patent review (2011 - 2014).
    Consalvi S; Biava M; Poce G
    Expert Opin Ther Pat; 2015; 25(12):1357-71. PubMed ID: 26566186
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prevention of cancer in the upper gastrointestinal tract with COX-inhibition. Still an option?
    Jiménez P; García A; Santander S; Piazuelo E
    Curr Pharm Des; 2007; 13(22):2261-73. PubMed ID: 17691999
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Current topics in the regulation of prostanoids-1. Inducible cyclooxygenase COX-2 and selective blockers].
    Ohara M; Sawa T
    Masui; 1998 Nov; 47(11):1325-32. PubMed ID: 9852696
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs: gastrointestinal-sparing potential drugs.
    Singh R; Kumar R; Singh DP
    J Med Food; 2009 Feb; 12(1):208-18. PubMed ID: 19298218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.